64 - Out With the Old, in With the New: Time to Update the Management of Staphylococcus aureus Infections

Monday, October 20, 2025

1:45 PM - 3:00 PM US ET

Location: Ballroom (Hall B1)

CME Credits: Maximum of 1.25 hours of AMA PRA Category 1 Credit™
MOC Credits: Maximum of 1.25 hours of MOC Credit
CNE Credits: Maximum of 1.25 hours of ANCC Credit
ACPE Credits: ACPE 1.25 knowledge-based contact hours of pharmacy CE
ACPE Number: JA0007082-9999-24-002-L01-P
PACE Credits: Maximum of 1 of PACE contact hours
CE Broker: Maximum of 1 CE broker credit hours

Debate Style Moderator(s)

David Cluck, PharmD, FIDSA, BCPS, BCIDP, AAHIVP (he/him/his)

Associate Professor of Pharmacy Practice
Pharmacy Practice
ETSU Bill Gatton College of Pharmacy
Johnson City, TN, United States
Edo-Abasi McGee, PharmD (she/her/hers)

Associate Professor and Director of Student Professional Development
Philadelphia College of Osteopathic Medicine, School of Pharmacy- GA campus, GA, United States

Faculty(s)

Carlo Tascini, MD (he/him/his)

First class Professor
University of Udine
Udine, Italy
Nicholas Turner, MD, MHSc

Assistant Professor
Internal Medicine - Division of Infectious Diseases
Duke University Medical Center
Durham, NC, United States
Rachel Britt, PharmD, BCIDP

Clinical Practice Specialist – Infectious Diseases
Pharmacy
University Health System
San Antonio, TX, United States
Warren Rose, PharmD, MPH

Associate Professor
Pharmacy
University of Wisconsin-Madison
Madison, WI, United States

Disclosure(s):

David B. Cluck, PharmD, FIDSA, BCPS, BCIDP, AAHIVP: Astellas, Inc: Advisor/Consultant

Edo-Abasi McGee, PharmD: No financial relationships to disclose.

Carlo Tascini, MD: A. Menarini Industrie Farmaceutiche Riunite S.R.L.: Honoraria; AdvanzPharma: Advisor/Consultant, Honoraria; Angelini: Honoraria; Beckman-Coulter: Honoraria; Biotest: Honoraria; DiaSorin: Honoraria; Gilead: Honoraria; Hikma: Advisor/Consultant, Honoraria; INFECTOPHARM: Honoraria; Merck, Sharpe & Dohme: Advisor/Consultant, Honoraria; Pfizer, Inc.: Advisor/Consultant, Honoraria; Thermo Fisher, Inc.: Advisor/Consultant, Honoraria; Viatris: Advisor/Consultant, Honoraria

Nicholas A. Turner, MD, MHSc: Basilea: Clinical trial adjudicator for ceftobiprole; PDI: Grant/Research Support; Purio Labs: Grant/Research Support

Rachel S. Britt, PharmD, BCIDP: No financial relationships to disclose.

Warren Rose, PharmD, MPH: AbbVie Inc: Honoraria; Pfizer, Inc.: Grant/Research Support

Learning Objectives:

At the conclusion of this session, participants will be able to:

compare and contrast vancomycin to other available agents in the management of invasive methicillin-resistant Staphylococcus aureus infections;
defend the current place in therapy of vancomycin for methicillin-resistant Staphylococcal infections;
select clinical situations where ceftobiprole may be considered over ceftaroline for invasive Staphylococcal infections;
appraise the role of ceftaroline in the management of Staphylococcus aureus bacteremia.

Presentations:

1:45 PM - 2:03 PM US ET

Should Vancomycin Be Replaced in the MRSA Guidelines? - Con
Debate Style Speaker: Rachel S. Britt, PharmD, BCIDP – University Health System
2:03 PM - 2:21 PM US ET

Should Vancomycin Be Replaced in the MRSA Guidelines? - Pro
Debate Style Speaker: Carlo Tascini, MD (he/him/his) – University of Udine
2:21 PM - 2:39 PM US ET

Should Ceftobiprole Replace Ceftaroline in the Management of Persistent Staphylococcal Bacteremia? - Pro
Debate Style Speaker: Nicholas A. Turner, MD, MHSc – Duke University Medical Center
2:39 PM - 3:00 PM US ET

Should Ceftobiprole Replace Ceftaroline in the Management of Persistent Staphylococcal Bacteremia? - Con
Debate Style Speaker: Warren Rose, PharmD, MPH – University of Wisconsin-Madison